Overview
Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2026-08-01
2026-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
CVRx, Inc.
Criteria
Inclusion Criteria:- Actively participating in the Neo Non-Randomized Hypertension Study.
- Have signed a revised approved informed consent form for continued participation in
this study.
Exclusion Criteria:
- Treating physician decision that the subject should not continue with therapy.